Pacer Advisors, Inc. Zentalis Pharmaceuticals, Inc. Transaction History

Pacer Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$4.09 - $16.13 $1,770 - $6,984	-433 Reduced 31.24%	953 $3,000
Q1 2024 May 10, 2024	BUY	$10.83 - $16.49 $15,010 - $22,855	1,386 New	1,386 $21,000
Q2 2021 Jul 21, 2021	SELL	$37.41 - $62.25 $57,237 - $95,242	-1,530 Closed	0 $0
Q1 2021 Apr 05, 2021	BUY	$35.69 - $52.72 $23,412 - $34,584	656 Added 75.06%	1,530 $66,000
Q4 2020 Jan 20, 2021	BUY	$31.71 - $57.97 $27,714 - $50,665	874 New	874 $45,000

147

65.3M

43.2K

21.7K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $132M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.